Clinical Positioning and Future Prospects of JAK Inhibitors in Alopecia Areata

    March 2026 in “ Expert Opinion on Pharmacotherapy ”
    M. Wada-Irimada, Takehiro Takahashi, Y. Asano
    Studysummary This review highlights that JAK inhibitors have transformed severe alopecia areata treatment by disrupting disease signaling, emphasizing the need for strategies to address non-responders and manage treatment discontinuation.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →

    Research cited in this study 51

    1. Ritlecitinib in Alopecia Areata: A 24-Week Real-World Experience Contrasting JAK Inhibitor-Naïve and JAK Inhibitor-Experienced Patients The Journal of Dermatology · 2025
    2. Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy Allergy · 2025
    3. Long-Term Real-World Outcomes of Baricitinib in Severe Alopecia Areata: A 104-Week Retrospective Analysis From a Single Institute The Journal of Dermatology · 2025
    4. Single-Cell Analysis of Temporal Immune Cell Dynamics in Alopecia Areata Reveals a Causal Role for Clonally Expanded CD8+ T Cells in Disease Cell Reports · 2025
    5. Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib PubMed · 2025
    6. Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme Journal of the European Academy of Dermatology and Venereology · 2025
    7. Predictive Factors for Treatment Responses to Baricitinib in Severe Alopecia Areata: A Retrospective, Multivariate Analysis of 70 Cases from a Single Center The Journal of Dermatology · 2025
    8. Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study Journal of the European Academy of Dermatology and Venereology · 2025
    9. Hidradenitis Suppurativa Tunnels: Unveiling a Unique Disease Entity JID Innovations · 2025
    10. Clinical Efficacy and Safety of Baricitinib in Patients With Alopecia Areata in Korea Annals of Dermatology · 2025
    11. Continued Treatment With Baricitinib Results in Meaningful Scalp Responses Among Scalp Non-Responder Patients With Eyebrow/Eyelash Regrowth in the First Year Journal of the European Academy of Dermatology and Venereology · 2024
    12. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata JAMA Dermatology · 2024
    13. Alopecia Areata Exhibits Cutaneous And Systemic OX40 Activation Across Atopic Backgrounds Allergy · 2024
    14. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    15. Real-World Effectiveness and Safety of Tofacitinib for Alopecia Areata: A Retrospective Cohort Study of 202 Patients Australasian Journal of Dermatology · 2024
    16. Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2 Journal of the European Academy of Dermatology and Venereology · 2024
    17. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program American journal of clinical dermatology · 2024
    18. Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients Acta dermato-venereologica · 2024
    19. Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials British Journal of Dermatology · 2023
    20. Combination of Baricitinib and Conventional Immunomodulating Therapy for Alopecia Totalis Skin Research and Technology · 2023
    21. Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata: Results from the ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Trial Pediatric Dermatology · 2023
    22. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    23. Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population JAMA Dermatology · 2023
    24. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    25. Prevalence, Comorbidities, and Treatment Patterns of Japanese Patients with Alopecia Areata: A Descriptive Study Using Japan Medical Data Center Claims Database The Journal of Dermatology · 2022
    26. Sisaipho Alopecia Areata Treated With Tofacitinib and Oral Minoxidil JAAD case reports · 2022
    27. Whole Exome Sequencing in Alopecia Areata Identifies Rare Variants in KRT82 Nature communications · 2022
    28. Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial Journal of the American Academy of Dermatology · 2021
    29. Clinical Response to Adjunctive Platelet-Rich Plasma Injections in a Patient with Alopecia Universalis on Oral Tofacitinib JAAD case reports · 2021
    30. The Epidemiology of Alopecia Areata: A Population-Based Cohort Study in UK Primary Care British Journal of Dermatology · 2021
    31. Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata JCI insight · 2021
    32. Immunological Properties of Atopic Dermatitis-Associated Alopecia Areata International Journal of Molecular Sciences · 2021
    33. Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata Experimental dermatology · 2020
    34. Alopecia Areata Susceptibility Variant in MHC Region Impacts Expressions of Genes Contributing to Hair Keratinization and Is Involved in Hair Loss EBioMedicine · 2020
    35. Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia Areata JAMA Dermatology · 2019
    36. High-Throughput T Cell Receptor Sequencing Identifies Clonally Expanded CD8+ T Cell Populations in Alopecia Areata JCI insight · 2018
    37. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    38. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    39. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    40. Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2015
    41. Epidemiology and Burden of Alopecia Areata: A Systematic Review Clinical, Cosmetic and Investigational Dermatology · 2015
    42. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015
    43. Inhibiting Janus Kinases to Treat Alopecia Areata Nature medicine · 2014
    44. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    45. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014
    46. Multivariate Analysis of Prognostic Factors in Patients With Rapidly Progressive Alopecia Areata Journal of The American Academy of Dermatology · 2012
    47. Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity Nature · 2010
    48. Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack Journal of Investigative Dermatology · 2007
    49. Major Histocompatibility Complex Class I Chain-Related Gene A Polymorphisms and Extended Haplotypes Are Associated with Familial Alopecia Areata Journal of Investigative Dermatology · 2005
    50. Alopecia Areata: A Tissue-Specific Autoimmune Disease of the Hair Follicle Autoimmunity Reviews · 2005
    51. Acute Diffuse and Total Alopecia of the Female Scalp Dermatology · 2002